108605
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
宫颈腺鳞癌继发脑腺癌及盆腔鳞癌一例报告并文献复习
Authors Liu P, Miao X , Xu Q, Li Z, Lu W, Li J
Received 26 March 2025
Accepted for publication 19 September 2025
Published 25 September 2025 Volume 2025:17 Pages 3259—3270
DOI https://doi.org/10.2147/IJWH.S526108
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Matteo Frigerio
Panbo Liu,1 Xinyu Miao,1 Qiqi Xu,1 Zhuoyao Li,1 Weiwei Lu,2,* Jiajia Li1,3,*
1Department of Gynecology, The First Hospital of Jilin University, Changchun, People’s Republic of China; 2Department of Blood Transfusion, The First Hospital of Jilin University, Changchun, People’s Republic of China; 3Jilin Provincial Key Laboratory of Female Reproductive Health, Changchun, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jiajia Li, Department of Gynecologic Oncology, Gynecology and Obstetrics Centre, the First Hospital of Jilin University, Changchun, Jilin, 130041, People’s Republic of China, Tel +8618804312859, Email lijiajia@jlu.edu.cn Weiwei Lu, Department of Blood Transfusion, the First Hospital of Jilin University, Changchun, Jilin, 130012, People’s Republic of China, Tel +86 13394310777, Email luww@jlu.edu.cn
Background: Cervical adenosquamous carcinoma (ASC) has a poor prognosis, and brain metastasis (BM) is extremely rare. Patients with BM have a poor prognosis. At present, there is no satisfactory treatment and no standard effective treatment. In recent years, immune checkpoint inhibitors (ICIs) and surgical treatment have emerged as a promising treatment for recurrent and metastatic cervical cancer (CC).
Case: We report a 39-year-old CC patient whose cervical biopsy pathology showed adenocarcinoma with stage IIIC1r, and so underwent radical radiotherapy and chemotherapy 7 years ago. She was under a palliative enterostomy 4 years ago after intestinal perforation due to multiple recurrence of pelvic tumor. To our surprise, postoperative histopathology was squamous cell carcinoma and adenocarcinoma, ASC was confirmed. The postoperative efficacy of intravenous chemotherapy combined with immunotherapy was partial response (PR), and the efficacy of immunomaintenance therapy was progressive disease (PD). While she had gone through the recurrence of intestinal leakage 3 years ago, Pelvic exenteration (PE) was performed (postoperative histopathology squamous cell carcinoma), the postoperative effect was complete response (CR), and the patient selected regular reexamination. Isolated BM focus was developed in August 2024, and radiotherapy, chemotherapy and immunotherapy were refused after surgical treatment (postoperative histopathology adenocarcinoma). The progression-free survival (PFS) after BM is nearly one year. At present, the patient’s reexamination showed no obvious abnormality.
Conclusion: We report a case of ASC, whose at the initial treatment, the cervical lesions were mainly adenocarcinoma. However, pelvic metastatic lesion was mainly squamous carcinoma and underwent chemotherapy combined with immunotherapy combined with PE. The histopathology form of BM is adenocarcinoma. The surgical treatment has achieved remarkable curative effect and survival benefit.The choice of treatment is often based on the number of metastases in the patient’s clinical state, tumor size, and metastases in other organs.
Keywords: brain metastases, cervical adenosquamous carcinoma, cervical cancer, immunotherapy, pelvic exenteration
1Department of Gynecology, The First Hospital of Jilin University, Changchun, People’s Republic of China; 2Department of Blood Transfusion, The First Hospital of Jilin University, Changchun, People’s Republic of China; 3Jilin Provincial Key Laboratory of Female Reproductive Health, Changchun, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jiajia Li, Department of Gynecologic Oncology, Gynecology and Obstetrics Centre, the First Hospital of Jilin University, Changchun, Jilin, 130041, People’s Republic of China, Tel +8618804312859, Email lijiajia@jlu.edu.cn Weiwei Lu, Department of Blood Transfusion, the First Hospital of Jilin University, Changchun, Jilin, 130012, People’s Republic of China, Tel +86 13394310777, Email luww@jlu.edu.cn
Background: Cervical adenosquamous carcinoma (ASC) has a poor prognosis, and brain metastasis (BM) is extremely rare. Patients with BM have a poor prognosis. At present, there is no satisfactory treatment and no standard effective treatment. In recent years, immune checkpoint inhibitors (ICIs) and surgical treatment have emerged as a promising treatment for recurrent and metastatic cervical cancer (CC).
Case: We report a 39-year-old CC patient whose cervical biopsy pathology showed adenocarcinoma with stage IIIC1r, and so underwent radical radiotherapy and chemotherapy 7 years ago. She was under a palliative enterostomy 4 years ago after intestinal perforation due to multiple recurrence of pelvic tumor. To our surprise, postoperative histopathology was squamous cell carcinoma and adenocarcinoma, ASC was confirmed. The postoperative efficacy of intravenous chemotherapy combined with immunotherapy was partial response (PR), and the efficacy of immunomaintenance therapy was progressive disease (PD). While she had gone through the recurrence of intestinal leakage 3 years ago, Pelvic exenteration (PE) was performed (postoperative histopathology squamous cell carcinoma), the postoperative effect was complete response (CR), and the patient selected regular reexamination. Isolated BM focus was developed in August 2024, and radiotherapy, chemotherapy and immunotherapy were refused after surgical treatment (postoperative histopathology adenocarcinoma). The progression-free survival (PFS) after BM is nearly one year. At present, the patient’s reexamination showed no obvious abnormality.
Conclusion: We report a case of ASC, whose at the initial treatment, the cervical lesions were mainly adenocarcinoma. However, pelvic metastatic lesion was mainly squamous carcinoma and underwent chemotherapy combined with immunotherapy combined with PE. The histopathology form of BM is adenocarcinoma. The surgical treatment has achieved remarkable curative effect and survival benefit.The choice of treatment is often based on the number of metastases in the patient’s clinical state, tumor size, and metastases in other organs.
Keywords: brain metastases, cervical adenosquamous carcinoma, cervical cancer, immunotherapy, pelvic exenteration